Insmed (INSM) closed at $141.33 on November 20, 2026, down 2.2% from the previous close, on volume of 5,379,766 shares (30-day average 3,579,510).
Data as of November 20, 2026.
20-Nov-2026
| # | Date | Strategy | Legs | Contracts |
|---|---|---|---|---|
| 1 | Oct 27, 2026 | Call Spread | 15-Jan-27100 : 130 C | 20,166 |
| 2-3 | The next 2 largest trades are for Premium members. Start a 7-day free trial | |||
Ranked by contracts: multi-leg trades of 200 or more contracts on one day, through Nov 20, 2026. See the largest for 5, 30, 60 and 90 days
Analysts Offer Insights on Healthcare Companies: Insmed (INSM) and Tyra Bioscience (TYRA)
TipRanks (Fri, 20-Nov 7:30 AM ET)
Insmed may be worth $170 to $210 a share in takeover, analyst
Seeking Alpha News (Thu, 19-Nov 2:01 PM ET)
Insmed’s Brinsupri Momentum and Strategic Appeal Support a Buy Rating
TipRanks (Thu, 19-Nov 12:55 PM ET)
Insmed: Strong Brinsupri Launch and Takeover Potential Support Buy Rating; $158 Target Unchanged
TipRanks (Thu, 19-Nov 12:55 PM ET)
Insmed’s New Pediatric Rare-Disease Study Offers an Early Pipeline Signal
TipRanks (Thu, 19-Nov 11:31 AM ET)
Insmed jumps on report of Sanofi takeover interest
Seeking Alpha News (Thu, 19-Nov 10:14 AM ET)
Analysts Offer Insights on Healthcare Companies: Krystal Biotech (KRYS) and Insmed (INSM)
TipRanks (Wed, 18-Nov 8:50 PM ET)
Insmed to Present at November and December 2026 Investor Conferences
PRNewswire (Wed, 4-Nov 7:00 AM ET)
Insmed soars as BRINSUPRI hits $400.10 million in Q3 revenue and 2026 guidance rises
Market Chameleon (Thu, 29-Oct 7:05 AM ET)
Insmed Reports Third-Quarter 2026 Financial Results and Provides Business Update
PRNewswire (Thu, 29-Oct 7:01 AM ET)
Insmed Inc is a biopharmaceutical company. Its commercial portfolio and clinical pipeline are organized around three therapeutic areas: Respiratory, Immunology and Inflammation, and Neuro and Other Rare. The company's two commercial products, Arikayce and Brinsupri, are both part of the Respiratory therapeutic area. The firm's clinical-stage programs are TPIP, INS1148, brensocatib, and INS1201, focusing on different therapeutic areas. Additionally, Insmed's pre-clinical research programs encompass various technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue. Geographically, the company generates maximum revenue from the United States from the sale of its commercial products.
Insmed trades on the NASDAQ stock market under the symbol INSM.
As of November 20, 2026, INSM stock price declined to $141.33 with 5,379,766 million shares trading.
INSM has a beta of -0.23, meaning it tends to be less sensitive to market movements. INSM has a correlation of 0.00 to the broad based SPY ETF.
INSM has a market cap of $31.01 billion. This is considered a Large Cap stock.
Last quarter Insmed reported $524 million in Revenue and -$.46 earnings per share. This beat revenue expectation by $25 million and missed earnings estimates by -$.09.
In the last 3 years, INSM traded as high as $212.75 and as low as $21.92.
The top ETF exchange traded funds that INSM belongs to (by Net Assets): VTI, VXF, VB, VO, IBB.
INSM has underperformed the market in the last year with a return of -29.2%, while SPY returned +6.9%. This shows that you would have done better investing in the overall market (through SPY) over the last year than in INSM shares. However, INSM has outperformed the market in the last 3 month and 2 week periods, returning +13.0% and +23.5%, while SPY returned -9.3% and -6.2%, respectively. This indicates INSM has been having a stronger performance recently.
INSM support price is $139.48 and resistance is $149.44 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that INSM shares will trade within this expected range on the day.